Anxiety

Neurology
7
Pipeline Programs
11
Companies
21
Clinical Trials
2 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
2
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
DULOXETINE HYDROCHLORIDEApproved
duloxetine
Unknown Company
oral2019

Competitive Landscape

10 companies ranked by most advanced pipeline stage

UP
UCB PharmaBelgium - Brussels
1 program
1
Alprazolam orally disintegrating tabletsPhase 31 trial
Active Trials
NCT00139854CompletedEst. Nov 2004
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
duloxetinePhase 31 trial
Active Trials
NCT00475969Completed327Est. Jun 2005
N
NeurocentriaCA - Walnut Creek
1 program
1
Low Dose MMFS-205-SRPhase 21 trial
Active Trials
NCT03601169CompletedEst. Jan 2019
Acadia Pharmaceuticals
1 program
1
ProbioticsPhase 21 trial
Active Trials
NCT02035878Unknown75Est. Apr 2014
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
2
AZD6280Phase 11 trial
AZD7325Phase 15 trials
Active Trials
NCT00681746Completed8Est. Sep 2008
NCT00940641Suspended8Est. Oct 2009
NCT00945425Terminated48Est. Nov 2009
+3 more trials
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Acceptance and Commitment TherapyN/A1 trial
Active Trials
NCT04236505CompletedEst. Oct 2019
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Doing What Matters in Times of StressN/A1 trial
Active Trials
NCT06979089Recruiting518Est. Sep 2026
Providence Therapeutics
1 program
Participant guided peer support gatheringN/A1 trial
Active Trials
NCT05988996Enrolling By InvitationEst. Jun 2026
Travere Therapeutics
1 program
Rare Group Problem Management PlusN/A1 trial
Active Trials
NCT06548022Active Not RecruitingEst. Nov 2025
Vera Therapeutics
Vera TherapeuticsBRISBANE, CA
1 program
Virtual reality glassesN/A1 trial
Active Trials
NCT07270445RecruitingEst. Mar 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Boehringer Ingelheimduloxetine
UCB PharmaAlprazolam orally disintegrating tablets
NeurocentriaLow Dose MMFS-205-SR
Acadia PharmaceuticalsProbiotics
AstraZenecaAZD7325
AstraZenecaAZD7325
AstraZenecaAZD7325
AstraZenecaAZD7325
AstraZenecaAZD7325
AstraZenecaAZD7325
AstraZenecaAZD7325
AstraZenecaAZD7325
AstraZenecaAZD7325
AstraZenecaAZD7325
AstraZenecaAZD6280

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 2,374 patients across 21 trials

NCT00475969Boehringer Ingelheimduloxetine

Duloxetine vs Placebo in the Treatment of General Anxiety

Start: Aug 2004Est. completion: Jun 2005327 patients
Phase 3Completed
NCT00139854UCB PharmaAlprazolam orally disintegrating tablets

A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety

Start: Aug 2004Est. completion: Nov 2004
Phase 3Completed
NCT03601169NeurocentriaLow Dose MMFS-205-SR

Comparison of MMFS Dosages in Older Adults

Start: Jul 2018Est. completion: Jan 2019
Phase 2Completed
NCT02035878Acadia PharmaceuticalsProbiotics

Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression

Start: Aug 2012Est. completion: Apr 201475 patients
Phase 2Unknown
NCT00808249AstraZenecaAZD7325

AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)

Start: Dec 2008Est. completion: May 2009725 patients
Phase 2Completed
NCT00807937AstraZenecaAZD7325

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

Start: Dec 2008Est. completion: May 2009369 patients
Phase 2Completed
NCT00940641AstraZenecaAZD7325

Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration

Start: Aug 2009Est. completion: Oct 20098 patients
Phase 1Suspended
NCT00945425AstraZenecaAZD7325

AZD7325 Japan Multiple Ascending Dose (MAD) Study

Start: Jul 2009Est. completion: Nov 200948 patients
Phase 1Terminated
NCT00902772AstraZenecaAZD7325

Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users

Start: May 2009Est. completion: Sep 2009100 patients
Phase 1Completed
NCT00901290AstraZenecaAZD7325

Determine the Effects of C-administration of AZD7325 and an Oral Contraceptive in Healthy Female Subjects

Start: May 2009Est. completion: Sep 200956 patients
Phase 1Suspended
NCT00769899AstraZenecaAZD7325

AZD7325 Single Ascending Dose Study in Healthy Male Japanese Subjects

Start: Oct 2008Est. completion: Mar 200948 patients
Phase 1Completed
NCT00790114AstraZenecaAZD7325

Determine the Effect of Multiple Doses of AZD7325, CYP Study

Start: Jul 2008Est. completion: Sep 200824 patients
Phase 1Completed
NCT00720421AstraZenecaAZD7325

A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.

Start: Jun 2008Est. completion: Aug 200816 patients
Phase 1Completed
NCT00681915AstraZenecaAZD7325

AZD7325 Multiple Ascending Dose Study

Start: Mar 2008Est. completion: Jul 200848 patients
Phase 1Completed
NCT00681746AstraZenecaAZD6280

Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280

Start: Feb 2008Est. completion: Sep 20088 patients
Phase 1Completed
NCT00681720AstraZenecaAZD7325

Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325

Start: Feb 2008Est. completion: Jul 20084 patients
Phase 1Completed
NCT07270445Vera TherapeuticsVirtual reality glasses

Effect of Virtual Reality Use on Preoperative Anxiety

Start: Jan 2026Est. completion: Mar 2027
N/ARecruiting
NCT06979089Heidelberg PharmaDoing What Matters in Times of Stress

Implementation of DWM in Dutch SMEs

Start: May 2025Est. completion: Sep 2026518 patients
N/ARecruiting
NCT06548022Travere TherapeuticsRare Group Problem Management Plus

Rare Group Problem Management Plus

Start: Feb 2024Est. completion: Nov 2025
N/AActive Not Recruiting
NCT05988996Providence TherapeuticsParticipant guided peer support gathering

Peer Support Groups for Families With an Infant in the NICU

Start: Aug 2023Est. completion: Jun 2026
N/AEnrolling By Invitation
NCT04236505City TherapeuticsAcceptance and Commitment Therapy

Wait List Controlled Trial of Brief ACT and Brief MBSR-informed Group Interventions for Anxiety in a University Setting

Start: May 2019Est. completion: Oct 2019
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
7h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
7h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
8h ago

Director of Finance

CoMind
London, UK
8h ago

Electronics Engineering Manager

CoMind
London, UK
8h ago

Director of Information Technology

Zavation Medical Products
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 2,374 patients
11 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)